Summit Therapeutics Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Summit Therapeutics Inc. (SMMT) reported Increase (Decrease) in Prepaid Expense and Other Assets of $23.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-23.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-07-23
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $12.03M, a 523.10% increase year-over-year.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $11.01M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$1.21M, a 114.50% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$3.74M, a 4447.67% decline year-over-year.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was -$4.87M, a 166.02% decline from fiscal 2024.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $7.37M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was -$3.61M.
- Summit Therapeutics Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was -$5.11M.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $12.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $23.05M 10-Q · filed 2026-07-23 | $21.84M derived: sum of 3 quarters · filed 2026-07-23 | $18.10M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2026-03-31 | $11.01M 10-Q · filed 2026-04-30 | $9.81M derived: sum of 2 quarters · filed 2026-04-30 | $6.07M derived: sum of 3 quarters · filed 2026-04-30 | $8.00M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-12-31 | -$1.21M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | -$4.95M derived: sum of 2 quarters · filed 2026-02-23 | -$3.02M derived: sum of 3 quarters · filed 2026-07-23 | -$4.87M 10-K · filed 2026-02-23 | |
| 2025-09-30 | -$3.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$1.81M derived: sum of 2 quarters · filed 2026-07-23 | -$3.66M 10-Q · filed 2025-10-20 | $4.67M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-23 | $81.00K 10-Q · filed 2026-07-23 | $8.41M derived: sum of 3 quarters · filed 2026-07-23 | $8.50M derived: sum of 4 quarters · filed 2026-07-23 | |
| 2025-03-31 | -$1.85M 10-Q · filed 2026-04-30 | $6.48M derived: sum of 2 quarters · filed 2026-04-30 | $6.57M derived: sum of 3 quarters · filed 2026-04-30 | $3.44M derived: sum of 4 quarters · filed 2026-04-30 | |
| 2024-12-31 | $8.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $8.41M derived: sum of 2 quarters · filed 2026-02-23 | $5.29M derived: sum of 3 quarters · filed 2026-02-23 | $7.37M 10-K · filed 2026-02-23 | $7.91M 10-K · filed 2025-02-24 |
| 2024-09-30 | $86.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-20 | -$3.03M derived: sum of 2 quarters · filed 2025-10-20 | -$959.00K 10-Q · filed 2025-10-20 | ||
| 2024-06-30 | -$3.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$1.04M 10-Q · filed 2025-08-11 | |||
| 2024-03-31 | $2.08M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | -$3.61M 10-K · filed 2026-02-23 | $914.00K 10-K · filed 2025-02-24 | |||
| 2022-12-31 | -$5.11M 10-K · filed 2025-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |